79 related articles for article (PubMed ID: 26463635)
1. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
2. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of Tim-3, PD-1, and CCR5 on peripheral T and B lymphocytes in hepatitis C virus-related hepatocellular carcinoma and their impact on treatment outcomes.
Zahran AM; Hetta HF; Rayan A; Eldin AS; Hassan EA; Fakhry H; Soliman A; El-Badawy O
Cancer Immunol Immunother; 2020 Jul; 69(7):1253-1263. PubMed ID: 32170378
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Tumor Hypoxia Modulation on sIL-2R Levels in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients Undergoing Chemotherapy: A Randomized Clinical Trial.
Rizky D; Tandarto K; Pangarsa EA; Naibaho RM; Kurniawan SP; Santosa D; Setiawan B; Suharti C
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1315-1324. PubMed ID: 38679992
[TBL] [Abstract][Full Text] [Related]
5. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
6. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
[TBL] [Abstract][Full Text] [Related]
7. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
Yu T; Xu-Monette ZY; Lagoo A; Shuai W; Wang B; Neff J; Carrillo LF; Carlsen ED; Pina-Oviedo S; Young KH
Front Immunol; 2024; 15():1335689. PubMed ID: 38348048
[TBL] [Abstract][Full Text] [Related]
9. Commentary: Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma.
Sun Z; Tan R; Wu H; Fang X
Front Immunol; 2024; 15():1377221. PubMed ID: 38698842
[No Abstract] [Full Text] [Related]
10. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.
Zhao M; Wang L; Wang X; He J; Yu K; Li D
Tumori; 2024 Jan; ():3008916231221636. PubMed ID: 38183180
[TBL] [Abstract][Full Text] [Related]
11. Advances in diagnosis, treatment and prognostic factors of gastrointestinal DLBCL.
Lai Q; Zhao Y; Yan H; Peng H
Leuk Res; 2023 Dec; 135():107406. PubMed ID: 37944240
[TBL] [Abstract][Full Text] [Related]
12. T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.
Chung DJ; Pronschinske KB; Shyer JA; Sharma S; Leung S; Curran SA; Lesokhin AM; Devlin SM; Giralt SA; Young JW
Cancer Immunol Res; 2016 Jan; 4(1):61-71. PubMed ID: 26464015
[TBL] [Abstract][Full Text] [Related]
13. LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy.
Peng W; Wu J; Feng J
Clin Exp Med; 2017 Feb; 17(1):1-8. PubMed ID: 26475621
[TBL] [Abstract][Full Text] [Related]
14. Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.
Cheng G; Li M; Wu J; Ji M; Fang C; Shi H; Zhu D; Chen L; Zhao J; Shi L; Xu B; Zheng X; Wu C; Jiang J
Int J Clin Exp Pathol; 2015; 8(8):9452-7. PubMed ID: 26464703
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
16. A New Therapeutic Era in GCB and ABC Diffuse Large B-cell Lymphoma Molecular Subtypes: A Cell of Origin-Driven Review.
Sandoval-Sus JD; Chavez J; Dalia S
Curr Cancer Drug Targets; 2016; 16(4):305-22. PubMed ID: 26517536
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicholas NS; Apollonio B; Ramsay AG
Biochim Biophys Acta; 2016 Mar; 1863(3):471-482. PubMed ID: 26554850
[TBL] [Abstract][Full Text] [Related]
18. Novel immunotherapies in lymphoid malignancies.
Batlevi CL; Matsuki E; Brentjens RJ; Younes A
Nat Rev Clin Oncol; 2016 Jan; 13(1):25-40. PubMed ID: 26525683
[TBL] [Abstract][Full Text] [Related]
19. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
20. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]